Analystreport

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was given a new $129.00 price target on by analysts at Cantor Fitzgerald. They now have a "buy" rating on the stock.

BioMarin Pharmaceutical Inc.  (BMRN) 
Last biomarin pharmaceutical inc. earnings: 4/29 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.biomarin.com